Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of fluticasone propionate + albuterol rescue inhaler for severe asthma exacerbations
MOH_2024-06-09_013461Phase 3Not yet recruiting
- Sponsor
- Syneos Health
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate and salbutamol in asthma (3 arms), sponsored by Syneos Health. Primary endpoint: Severe clinical asthma exacerbation events. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
fluticasone propionatesalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on MOH_2024-06-09_013461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-06-09_013461.